Interstitial Lung Disease Clinical Trials in Dallas, Texas
8 recruitingDallas, Texas
Showing 1–8 of 8 trials
Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Interstitial Lung DiseasePulmonary HypertensionPulmonary Hypertension Due to Lung Diseases and Hypoxia
United Therapeutics900 enrolled67 locationsNCT06388421
Recruiting
Phase 3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Progressive Pulmonary FibrosisInterstitial Lung Disease
United Therapeutics698 enrolled159 locationsNCT05943535
Recruiting
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Duke University3,000 enrolled44 locationsNCT01915511
Recruiting
Not Applicable
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Pulmonary HypertensionInterstitial Lung Disease (ILD)
Tempus AI900 enrolled25 locationsNCT06911632
Recruiting
Phase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Progressive Pulmonary FibrosisInterstitial Lung DiseasePulmonary Fibrosis+7 more
Avalyn Pharma Inc.375 enrolled152 locationsNCT06329401
Recruiting
Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research
Respiratory FailureLung DiseasesInterstitial Lung Disease
Baylor Research Institute100 enrolled1 locationNCT04664192
Recruiting
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Progressive Pulmonary FibrosisInterstitial Lung Disease
University of Massachusetts, Worcester500 enrolled13 locationsNCT06855329
Recruiting
Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Interstitial Lung Disease
aTyr Pharma, Inc.25 enrolled15 locationsNCT05892614